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Background  
VERSE is a PROBE trial, to determine whether two types of intensive aphasia therapy within 
14 days of acute stroke, provided for 20 sessions (minimum 15 hours), deliver greater 
therapeutic and cost-effectiveness than usual care with particular attention paid to monitoring 
of trial fidelity.  
 
Methods 
Eligible participants with acute post-stroke aphasia were stratified by aphasia severity and 
randomised to receive usual care, usual care-plus (usual ward-based therapy provided daily) 
or VERSE therapy (a prescribed aphasia therapy provided daily) starting within the first 15 
days following stroke (N=246). UC therapy is usual ward-based aphasia therapy; UC-Plus is 
usual ward-based therapy provided for 20 x 45-60 minute sessions (15-20 hours) within the 
first 50 days following stroke; VERSE therapy is a prescribed aphasia therapy provided at the 
same intensity as UC-Plus therapy. The primary outcome was the Aphasia Quotient of the 
Western Aphasia Battery at 12 weeks post stroke. Secondary outcomes included discourse 
analysis, Stroke and Aphasia Quality of Life (SAQoL-39), the Aphasia Depression Rating 
Scale, and resource use (for full cost evaluation) at 26 weeks post stroke. Therapy fidelity 
was measured according to the TIDiER statement with treatment adherence and treatment 
differentiation monitored throughout the trial. Clinicians in the UC-Plus and VERSE 
treatment arms were required to video record four therapy sessions (sessions 5, 10, 15 and 
20). These sessions were reviewed by the independent therapy fidelity monitor and feedback 
was provided to therapists as part of the ongoing adherence to the treatment protocol. Data 
analysis will be completed in September 2018. 
 
Results 
17 sites recruited participants to this trial. Of 12,462 people with confirmed stroke screened 
for this trial, 3240 (26%) had aphasia, 526 (16%) were trial eligible and 246 (47%) were 
recruited. Reasons for non-recruitment of the 280 eligible participants included discharged 
out of area or to a non-VERSE site (35%), 13% refused to participate, 6% had insufficient 
staff to cover therapy, and the remaining eligible participants were classified as for palliative 
care, recruited to another trial, or had aphasia that was either too mild or too severe for the 
trial.  
To date, data collection is ongoing with the last participant, last visit due late July 2018. Over 
10,452 speech pathology service events for all arms have been recorded. Of the received 
videorecorded sessions, therapy monitoring indicates treatment adherence to protocol is 80% 
and treatment differentiation is 100%. Full effectiveness and treatment fidelity results will be 
presented. 
Discussion 
VERSE is one of the largest clinical trials completed in aphasia intervention. It will be the 
first to report comprehensive treatment fidelity results that comply with the TIDiER 
statement for complex clinical trials.  With high levels of therapy fidelity, this clinical trial 
will contribute substantially to the early aphasia therapy debate. When complete, cost 
evaluation evidence for this trial will further contribute to the evidence base to provide a 
comprehensive overview of early aphasia recovery after stroke. 
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